HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seppic comes to rescue of aging face, bust

This article was originally published in The Rose Sheet

Executive Summary

Noting that with age, "the cheeks become hollow and the chest sags," Paris-based subsidiary of Air Liquide introduces Voluform, a 3D "plumping" active ingredient it says can remodel curves of the face and bust, presenting an alternative to cosmetic surgery and Botox injections. Voluform stimulates "functionality" of adipocytes, or fat cells, and prevents loss of volume and fullness, according to information presented at in-cosmetics. "With its plumping effect, it redefines the contours of the face, fills in wrinkles and rounds out the chest with original tautness and firmness," Seppic says. After one month of topical treatment on the bust area, 83% of testers saw increased breast volume, while 60% recorded an average size increase of 0.6 centimeters. Firm is positioning Voluform as "an active ingredient for each generation.

You may also be interested in...



Sanofi Bets Big On IO With Synthorx Buy

The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.

Global Industry Hails Bioequivalence Progress

For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.

Generics Leaders Trade Places At The Top

In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.

UsernamePublicRestriction

Register

RS016890

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel